Lineage Cell Therapeutics. has filed a patent for a method and composition to expand and maintain human embryonic stem cells (hESCs) in an undifferentiated, pluripotent state. The method involves combining hESCs, an extracellular matrix component, and a microcarrier in growth media to form a suspendable expansion complex, which is then cultured for a period of time. GlobalData’s report on Lineage Cell Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Lineage Cell Therapeutics, embryonic stem cell culturing was a key innovation area identified from patents. Lineage Cell Therapeutics's grant share as of September 2023 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Expansion of human embryonic stem cells using microcarriers
A recently filed patent (Publication Number: US20230313127A1) describes a method for expanding and maintaining human embryonic stem cells (hESCs) in an undifferentiated, pluripotent state. The method involves combining hESCs, an extracellular matrix component (ECM), and a microcarrier in growth media to form a suspendable expansion complex, which is then cultured for a period of time.
The patent claims that the microcarriers used in the method can be made of various materials such as polystyrene, cross-linked dextran, magnetic particles, microchips, cellulose, hydroxylated methacrylate, collagen, gelatin, polystyrene, plastic, glass, ceramic, silicone, or a combination thereof. These microcarriers can have different shapes, including spherical, smooth, macroporous, rod-shaped, or a combination of these.
The ECM component of the suspendable expansion complex can be matrigel, laminin, vitronectin, collagen, their derivatives, or a combination thereof. Specifically, the patent mentions the use of human laminin, particularly human laminin 511 E8 fragment.
The microcarriers used in the method can be either coated or uncoated. If coated, they can be coated with matrigel, laminin, vitronectin, collagen, their derivatives, or a combination thereof. The patent also mentions the possibility of coupling the microcarriers with protamine or polylysine.
The microcarriers can be neutral or negatively charged, and they are preferably hydrophilic. The suspendable expansion complex is cultured for at least one day, and it can be cultured for up to fourteen days. The cultured cells of the complex can be harvested and further expanded or differentiated by changing the growth medium.
The patent also describes a suspendable expansion complex composition, which includes hESCs, ECM, microcarriers, and a growth medium. The composition can have the same characteristics as mentioned above, including the choice of microcarrier materials, shapes, coating options, and charge.
Overall, this patent presents a method and composition for expanding and maintaining hESCs in an undifferentiated, pluripotent state. The use of specific microcarriers, ECM components, and culture conditions may contribute to the efficient expansion and maintenance of hESCs for various applications in regenerative medicine and research.
To know more about GlobalData’s detailed insights on Lineage Cell Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
